<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo>, affects approximately 1% of adults and prevalence increases with age </plain></SENT>
<SENT sid="1" pm="."><plain>Nine per cent of those aged 80 years and older have AF </plain></SENT>
<SENT sid="2" pm="."><plain>AF is associated with increased cardiovascular mortality and morbidity, including <z:hpo ids='HP_0001297'>stroke</z:hpo>.<z:hpo ids='HP_0001297'>Stroke</z:hpo> in patients with AF is more severe and more likely to be fatal </plain></SENT>
<SENT sid="3" pm="."><plain>Prevention of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> and rate or rhythm control are the main therapeutic strategies for patients with AF </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="6" ids="28384">Vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> reduce the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with AF, however are underutilized </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi> is the first antiarrhythmic drug that reduces the <z:hpo ids='HP_0001297'>stroke</z:hpo> rate </plain></SENT>
</text></document>